Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S205 H5N1 vaccine
- Development stage
- Discontinued
- Lead developer
- Abbott
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
S205 H5N1 vaccine is an egg-derived pandemic surface antigen influenza vaccine developed by Solvay Pharmaceuticals. It is designed to induce a specific immune response against the H5N1 influenza virus. The vaccine is being investigated for its immunogenicity and safety, utilizing various concentrations of H5N1 antigen and aluminium-hydroxide as an adjuvant.
- Other names
- subvirion inactivated influenza A/H5N1 vaccine + aluminium hydroxide
02
Targets
H1 HA (Influenza A hemagglutinin H1)
Beyond the preview
Go deeper on S205 H5N1 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S205 H5N1 vaccine.